SCHEMBL2470199

SCHEMBL2470199

CCc1ccc(CCNC(=O)C2(Cc3ccc(F)cc3)CCN(C(=O)CCc3ccccc3)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.50
PLAAT3 P53816 1/20 0.47
PLAAT5 Q96KN8 1/20 0.47
PLAAT2 Q9NWW9 1/20 0.47
PLAAT4 Q9UL19 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
EPHX2 P34913 1/20 0.46
NPC1 O15118 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 2/20 0.43
GPR183 P32249 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
FKBP1A P62942 1/20 0.42
RAB9A P51151 1/20 0.42
HPGD P15428 1/20 0.42
KDM1A O60341 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2472142 0.95 GFER (0.55) GFERPLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL2469409 0.95 GFER (0.55) GFERPLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL2471735 0.95 NPC1 (0.49) EPHX2NPC1TDP1ALDH1A1L3MBTL1
SCHEMBL2473963 0.92 ALDH1A1 (0.47) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1
SCHEMBL2468347 0.90 ALDH1A1 (0.55) PLAAT3PLAAT5PLAAT2PLAAT4EPHX2
SCHEMBL2472152 0.90 NPC1 (0.55) GFERPLAAT5PLAAT4EPHX2NPC1
SCHEMBL2468371 0.90 ALDH1A1 (0.52) TAAR1ALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL2469374 0.90 TAAR1 (0.45) GFERPLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL2472171 0.89 ALDH1A1 (0.46) GFERPLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL2472974 0.88 KMT2A (0.57) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 GFER 1562/4885PLAAT3 2175/4885PLAAT5 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.